BANK VONTOBEL/CALL/ROCHE GS/350/0.1/21.06.24 Stock

Warrant

DE000VV4MJM0

Delayed Deutsche Boerse AG 08:00:25 2024-05-17 EDT
0.001 EUR 0.00% Intraday chart for BANK VONTOBEL/CALL/ROCHE GS/350/0.1/21.06.24
3 months-88.89%
6 months-96.67%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-17 0.001 0.00%
24-05-16 0.001 0.00%
24-05-15 0.001 0.00%
24-05-14 0.001 0.00%
24-05-13 0.001 0.00%

Delayed Quote Deutsche Boerse AG

Last update May 17, 2024 at 08:00 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VV4MJM
ISINDE000VV4MJM0
Date issued 2022-07-04
Strike 350 CHF
Maturity 2024-06-21 (35 Days)
Parity 10 : 1
Emission price 2.13
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.72
Lowest since issue 0.001
Delta0.01x
Omega 19.25
Premium47.86x
Gearing1920.73x
Moneyness 0.6766
Difference Strike 113.6 CHF
Difference Strike %+32.44%
Spread 0.023
Spread %95.83%
Intrinsic value 0.000000

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
234.8 CHF
Average target price
279.4 CHF
Spread / Average Target
+18.99%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW